Stockreport

ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telang...

ChromaDex Corporation  (CDXC) 
NASDAQ:AMEX Investor Relations: investors.chromadex.com
PDF LOS ANGELES, June 07, 2024 BUSINESS WIRE ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD ) and healthy aging research, tod [Read more]